JPH0673084A - Glycoside and antihepatitic agent comprising the same - Google Patents
Glycoside and antihepatitic agent comprising the sameInfo
- Publication number
- JPH0673084A JPH0673084A JP4228756A JP22875692A JPH0673084A JP H0673084 A JPH0673084 A JP H0673084A JP 4228756 A JP4228756 A JP 4228756A JP 22875692 A JP22875692 A JP 22875692A JP H0673084 A JPH0673084 A JP H0673084A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- residue
- glycoside
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、新規なグリコシド及び
これを有効成分として含有する抗肝炎剤に関する。TECHNICAL FIELD The present invention relates to a novel glycoside and an anti-hepatitis agent containing the glycoside as an active ingredient.
【0002】[0002]
【従来の技術及び発明が解決しようとする課題】天然由
来のサポニンは、種々の薬理学的又は生理学的活性を有
することが知られており、これらの活性の発現にはサポ
ニンのアグリコンの構造のみならず、その分子中の糖の
種類、数、コンホメーション、結合様式などにも依存す
ると予想されている。BACKGROUND OF THE INVENTION Naturally-occurring saponins are known to have various pharmacological or physiological activities, and expression of these activities requires only the structure of the saponin aglycone. Of course, it is also expected to depend on the type, number, conformation, binding mode, etc. of sugars in the molecule.
【0003】これらのうち、生薬の甘草から単離された
グリチルリチンは、抗アレルギー作用、抗炎症作用を有
するため、現在臨床において、肝臓疾患用剤として使用
されている。しかしながら、このグリチルリチンは、人
に大量に投与すると浮腫や高血圧を引き起こすことが報
告されている(A.Kumagai,Y.Tamur
a,C.Y.Ing,現代東洋医学,12,38(19
81))。Of these, glycyrrhizin isolated from licorice, which is a crude drug, has an antiallergic action and an antiinflammatory action, and is currently used clinically as a drug for liver diseases. However, it has been reported that this glycyrrhizin causes edema and hypertension when administered to humans in large amounts (A. Kumagai, Y. Tamur.
a, C.I. Y. Ing, Contemporary Oriental Medicine, 12 , 38 (19
81)).
【0004】従って、このような副作用を軽減した肝臓
疾患用剤が望まれていた。Therefore, there has been a demand for a drug for liver diseases in which such side effects are reduced.
【0005】[0005]
【課題を解決するための手段】かかる実情において、本
発明者らは鋭意研究を行なった結果、後記一般式(A)
で表わされるグリコシドが、優れた抗肝炎作用を有し、
しかも副作用の少ないことを見出し、本発明を完成し
た。Under such circumstances, as a result of intensive studies conducted by the present inventors, the following general formula (A) was obtained.
The glycoside represented by has an excellent anti-hepatitis action,
Moreover, they have found that there are few side effects, and have completed the present invention.
【0006】すなわち、本発明は、次の一般式(A)That is, the present invention provides the following general formula (A):
【0007】[0007]
【化2】 [Chemical 2]
【0008】〔式中、R1 は水素原子、低級アルキル基
又はヒドロキシ基が低級アルカノイル基で保護されてい
てもよい単糖残基、二糖残基若しくは三糖残基を示し、
R2 は水素原子、メチル基又はヒドロキシメチル基を示
し、R3 及びR8 はヒドロキシ基、−CH2OR3′又は
−COOR8′(ここでR3′は水素原子又は低級アルカ
ノイル基を示し、R8′は水素原子又は低級アルキル基
を示す)を示し、R4及びR5 のいずれか一方、R6 及
びR7 のいずれか一方又はR9 及びR10のいずれか一方
は水素原子を、他方はヒドロキシ基又は低級アルカノイ
ルオキシ基を示し、R11及びR12のいずれか一方又はR
13及びR14のいずれか一方は水素原子を、他方はヒドロ
キシ基、低級アルカノイルオキシ基又はヒドロキシ基が
低級アルカノイル基で保護されていてもよい単糖残基を
示す(ただし、当該他方のうちの一つはヒドロキシ基又
は低級アルカノイルオキシ基を示す)〕で表わされるグ
リコシド及びこれを有効成分として含有する抗肝炎剤を
提供するものである。[In the formula, R 1 represents a monosaccharide residue, a disaccharide residue or a trisaccharide residue in which a hydrogen atom, a lower alkyl group or a hydroxy group may be protected by a lower alkanoyl group,
R 2 represents a hydrogen atom, a methyl group or a hydroxymethyl group, R 3 and R 8 represent a hydroxy group, —CH 2 OR 3 ′ or —COOR 8 ′ (wherein R 3 ′ represents a hydrogen atom or a lower alkanoyl group. , R 8 ′ represents a hydrogen atom or a lower alkyl group), and one of R 4 and R 5 , one of R 6 and R 7 , or one of R 9 and R 10 represents a hydrogen atom. , The other represents a hydroxy group or a lower alkanoyloxy group, and one of R 11 and R 12 or R
One of 13 and R 14 represents a hydrogen atom, and the other represents a hydroxy group, a lower alkanoyloxy group or a monosaccharide residue in which a hydroxy group may be protected by a lower alkanoyl group (provided that, One of which represents a hydroxy group or a lower alkanoyloxy group)] and an anti-hepatitis agent containing the glycoside as an active ingredient.
【0009】本発明のグリコシド(A)において、低級
アルキル基としては炭素数1〜5の直鎖又は分岐鎖のア
ルキル基、例えばメチル基、エチル基、プロピル基、イ
ソプロピル基等が挙げられる。低級アルカノイル基とし
ては炭素数2〜5の直鎖又は分岐鎖のアルカノイル基、
例えばアセチル基、プロピオニル基、ブチリル基等が挙
げられる。また、低級アルカノイルオキシ基としては、
炭素数2〜5の直鎖又は分岐鎖のアルカノイルオキシ
基、例えばアセトキシ基、プロピオニルオキシ基、ブチ
リルオキシ基等が挙げられる。単糖残基としてはグルコ
ピラノシル基、ガラクトピラノシル基、グルクロノピラ
ノシル基等が挙げられる。二糖残基、三糖残基として
は、これら単糖類が2又は3個結合した基を挙げること
ができる。In the glycoside (A) of the present invention, examples of the lower alkyl group include linear or branched alkyl groups having 1 to 5 carbon atoms such as methyl group, ethyl group, propyl group and isopropyl group. The lower alkanoyl group is a linear or branched alkanoyl group having 2 to 5 carbon atoms,
Examples thereof include an acetyl group, a propionyl group, a butyryl group and the like. Further, as the lower alkanoyloxy group,
Examples thereof include linear or branched alkanoyloxy groups having 2 to 5 carbon atoms, such as acetoxy group, propionyloxy group and butyryloxy group. Examples of the monosaccharide residue include a glucopyranosyl group, a galactopyranosyl group, and a glucuronopyranosyl group. Examples of the disaccharide residue and the trisaccharide residue include groups in which two or three of these monosaccharides are bonded.
【0010】本発明のグリコシド(A)のうち、R1 が
糖のもの(C)は、例えば以下の方法に従って製造する
ことができる。Of the glycosides (A) of the present invention, those in which R 1 is a sugar (C) can be produced, for example, according to the following method.
【0011】[0011]
【化3】 [Chemical 3]
【0012】(式中、R1′はヒドロキシ基が低級アル
カノイル基で保護されていてもよい単糖残基、二糖残基
又は三糖残基を示し、R2 〜R14は前記と同じ意味を有
する)(In the formula, R 1 ′ represents a monosaccharide residue, a disaccharide residue or a trisaccharide residue in which a hydroxy group may be protected by a lower alkanoyl group, and R 2 to R 14 are the same as above. Has meaning)
【0013】すなわち、化合物(B)を、通常の方法に
より糖誘導体(1)〜(3)を用いてグリコシル化反応
を行うことにより、本発明のグリコシド(C)を製造す
ることができる。また、グリコシド(C)のうち、
R1′が単糖のものは、R1′が二糖のものを、β−グル
コシダーゼを用いて加水分解することにより、製造する
こともできる。ここで用いられるβ−グルコシダーゼと
しては、例えば、エムルシン等が挙げられる。That is, the glycoside (C) of the present invention can be produced by subjecting the compound (B) to a glycosylation reaction using the sugar derivatives (1) to (3) by a conventional method. In addition, among glycosides (C),
R 1 'thing monosaccharides, R 1' what is disaccharide, by hydrolysis with a β- glucosidase, it can also be produced. Examples of β-glucosidase used here include emulsin and the like.
【0014】また、本発明のグリコシド(A)のうち、
R1が水素原子又は低級アルキル基のものは、例えば以
下の方法により製造することができる。Among the glycosides (A) of the present invention,
When R 1 is a hydrogen atom or a lower alkyl group, it can be produced, for example, by the following method.
【0015】[0015]
【化4】 [Chemical 4]
【0016】[0016]
【化5】 [Chemical 5]
【0017】すなわち、オレアノール酸メチル(19)
と糖β−クロライド(20)を反応させて化合物(2
1)を得、これを脱トリクロロアセチル化して化合物
(23)となし、次いでこれと糖ブロマイド(24)を
反応させることにより、化合物(25)を得ることがで
きる。また、さらに脱保護基反応を行うことにより、化
合物(26)を得ることができる。That is, methyl oleanolate (19)
And a sugar β-chloride (20) are reacted with each other to produce a compound (2
Compound (25) can be obtained by obtaining 1), detrichloroacetylating this to give compound (23), and then reacting this with sugar bromide (24). Further, the compound (26) can be obtained by further performing a deprotecting group reaction.
【0018】上記の如くして得られる本発明化合物
(A)を抗肝炎剤として使用する場合、その投与量は患
者の体重、年令、性別、投与方法、体調、病状などによ
り異なるが、経口投与の場合は体重1kg当り一日に0.
4mg〜200mg、非経口投与の場合は体重1kg当り一日
に0.08mg〜40mg程度が適当である。When the compound (A) of the present invention obtained as described above is used as an anti-hepatitis agent, its dose varies depending on the patient's weight, age, sex, administration method, physical condition, medical condition, etc. In the case of administration, it is 0 per day per kg of body weight.
4 mg to 200 mg, and in the case of parenteral administration, about 0.08 mg to 40 mg per kg body weight per day is appropriate.
【0019】本発明の抗肝炎剤は、通常の方法で錠剤、
顆粒剤、散剤、カプセル剤、懸濁剤、注射剤、坐剤など
の種々の剤形とすることができる。経口用固型製剤を製
造するには、化合物(A)に賦形剤、更に必要に応じて
結合剤、崩壊剤、滑沢剤、着色剤、矯味矯臭剤、増量
剤、被覆剤、糖衣剤などを加えた後、常法により錠剤、
顆粒剤、散剤、カプセル剤、坐剤等とすることが好まし
い。注射剤を調製する場合は、化合物(A)を注射用蒸
留水等の水性担体の溶解、分散、乳化等することが好ま
しい。The anti-hepatitis agent of the present invention is a tablet prepared by a conventional method.
It can be made into various dosage forms such as granules, powders, capsules, suspensions, injections and suppositories. To produce an oral solid preparation, the compound (A) is used as an excipient, and if necessary, a binder, a disintegrating agent, a lubricant, a coloring agent, a flavoring agent, a bulking agent, a coating agent, a sugar coating agent. After adding, etc., tablets,
Granules, powders, capsules, suppositories and the like are preferable. When preparing an injection, it is preferable to dissolve, disperse, or emulsify the compound (A) in an aqueous carrier such as distilled water for injection.
【0020】[0020]
【発明の効果】本発明の化合物(A)は、以下に示す試
験例から明らかな如く、四塩化炭素で誘発される実験肝
障害モデルにおいて、AST、ALT活性を著しく抑制
し、顕著な肝障害抑制効果を示す。従って、本発明化合
物(A)を有効成分として含有する本発明の抗肝炎剤
は、優れた抗肝炎作用を有し、しかも副作用の少ないも
のである。The compound (A) of the present invention markedly inhibits AST and ALT activity in a model model of experimental liver injury induced by carbon tetrachloride, as is clear from the test examples shown below, and causes significant liver injury. Shows a suppressive effect. Therefore, the anti-hepatitis agent of the present invention containing the compound (A) of the present invention as an active ingredient has an excellent anti-hepatitis action and has few side effects.
【0021】[0021]
【実施例】次に、実施例を挙げて本発明を更に説明する
が、本発明はこれら実施例に限定されるものではない。 実施例1EXAMPLES Next, the present invention will be further described with reference to examples, but the present invention is not limited to these examples. Example 1
【0022】[0022]
【化6】 [Chemical 6]
【0023】(1)エステルグリコシデーション 化合物(4)1.0gを乾燥塩化メチレン20mlに溶解
し、無水硫酸カルシウム(W.A.Hammond D
rierite Co.製)6.0g及び炭酸銀850
mgを加えて1時間撹拌した後、化合物(2)4.0gト
リフルオロメタンスルホン酸銀(AgOTf)384mg
及び1,1,3,3−テトラメチル尿素(TMU)21
5μlを加えて再び36時間撹拌した。反応液を濾過し
た後、濾液を飽和重曹水溶液、水の順に洗浄し、硫酸マ
グネシウム上で乾燥後、減圧濃縮し、シリカゲルカラム
クロマトグラフィー(ベンゼン−アセトン、7.5%勾
配)に付し、油状物の残渣4.88gを得、さらに高速
液体クロマトグラフィー〔ODS 10mmφ×250mm
(20%水−メタノール)〕により、油状物のβ−グリ
コシド(5)830mg(収率51.3%)及びα−グリ
コシド(5′)73mg(収率4.5%)を得た。 化合物(5): FAB-MS m/z:1643[M+Na]+.1 H-NMR(CDCl3):表113 C-NMR(C5D5N):表2 Anal.Calcd for C79H112O35:C,58.51;H,6.96 Found C,58.51;H,7.01 化合物(5)のα−異性体(5′): FAB-MS m/z:1643[M+Na]+.1 H-NMR(CDCl3):表113 C-NMR(C5D5N):表2 Anal.Calcd for C79H112O35:C,58.51;H,6.96 Found C,58.19;H,7.11(1) Ester glycosidation 1.0 g of the compound (4) was dissolved in 20 ml of dry methylene chloride, and anhydrous calcium sulfate (WA Hammond D) was added.
rierite Co. Made) 6.0 g and silver carbonate 850
After adding mg and stirring for 1 hour, compound (2) 4.0 g Silver trifluoromethanesulfonate (AgOTf) 384 mg
And 1,1,3,3-tetramethylurea (TMU) 21
5 μl was added and the mixture was stirred again for 36 hours. After filtering the reaction solution, the filtrate was washed with a saturated aqueous solution of sodium bicarbonate and water in this order, dried over magnesium sulfate, concentrated under reduced pressure, and subjected to silica gel column chromatography (benzene-acetone, 7.5% gradient) to give an oil. 4.88 g of the residue of the product was obtained, and further high performance liquid chromatography [ODS 10 mmφ × 250 mm
(20% water-methanol)] to obtain 830 mg (yield 51.3%) of β-glycoside (5) and 73 mg (yield 4.5%) of α-glycoside (5 ′). Compound (5): FAB-MS m / z:. 1643 [M + Na] + 1 H-NMR (CDCl 3): Table 1 13 C-NMR (C 5 D 5 N): Table 2 Anal.Calcd for C 79 H 112 O 35 : C, 58.51; H, 6.96 Found C, 58.51; H, 7.01 α-isomer (5 ′) of compound (5): FAB-MS m / z: 1643 [M + Na] + . 1 H-NMR (CDCl 3 ): Table 1 13 C-NMR (C 5 D 5 N): Table 2 Anal.Calcd for C 79 H 112 O 35 : C, 58.51; H, 6.96 Found C, 58.19; H, 7.11
【0024】(2)脱アセチル化 化合物(5)450mgを5.0%水酸化カリウムメタノ
ール溶液2mlに溶解し、室温で1時間放置した後、酢酸
で中和(pH6〜7)した。次いで、イオン交換樹脂(ア
ンバーライトMB−3)に付し、溶出液にピリジンを加
えて減圧濃縮し、得られた残渣をカラムクロマトグラフ
ィー(クロロホルム:メタノール:水=65:35:1
0)で精製し、化合物(6)240mg(収率80.4
%)を得た。 FAB-MS m/z:1097[M+Na] +.13 C-NMR(C5D5N): 表3及び表4 参考例(2) Deacetylation Compound (5) (450 mg) was dissolved in 5.0% potassium hydroxide methanol solution (2 ml), allowed to stand at room temperature for 1 hour, and then neutralized with acetic acid (pH 6 to 7). Then, it was applied to an ion exchange resin (Amberlite MB-3), pyridine was added to the eluate and the mixture was concentrated under reduced pressure, and the obtained residue was subjected to column chromatography (chloroform: methanol: water = 65: 35: 1).
0) and 240 mg of compound (6) (yield 80.4
%) Was obtained. FAB-MS m / z:. 1097 [M + Na] + 13 C-NMR (C 5 D 5 N): Tables 3 and 4 Reference Example
【0025】[0025]
【化7】 [Chemical 7]
【0026】(1)化合物(8)の合成 D−グルコース20gを乾燥ピリジン300mlに溶解
し、トリフェニルメチルクロライド34gを加え、撹拌
して溶解した後、1晩放置した。反応液に無水酢酸30
0mlを加えて再び一昼夜撹拌した。反応液を氷水中に注
ぎ込み、塩化メチレンで抽出し、飽和重曹水溶液、水の
順に洗い、硫酸マグネシウム上で乾燥後減圧濃縮した。
得られた残渣を70%酢酸水溶液200mlに溶かして2
時間還流し、濾過した後、濾液を塩化メチレンで抽出
し、飽和重曹水溶液、水の順に洗浄し、硫酸マグネシウ
ム上で乾燥した後、減圧濃縮して残渣を得た。これを、
ジエチルエーテル/石油エーテルで再結晶して化合物
(7)32.07g(mp.40℃、収率82.9%)
を得た。化合物(7)5.4gを乾燥塩化メチレン20
mlに溶かし、無水硫酸カルシウム6.0g及び炭酸銀
4.3gを加えて1時間撹拌した後、化合物(2)1
3.0gを加えて再び一晩撹拌した。反応液を濾過し、
濾液を飽和重曹水溶液、水の順に洗浄し、硫酸マグネシ
ウム上で乾燥後減圧濃縮し、カラムクロマトグラフィー
(CH2Cl2−MeOH、1.0%勾配)に付し、化合
物(8)7.3g(収率48.7%)を得た。 化合物(8):FAB-MS m/z:989[M+Na]+. (2)化合物(3)の合成 氷冷下、化合物(8)5.6gを30%臭化水素酢酸溶
液150mlに溶解し、30分撹拌し、反応液を氷水中に
注ぎ込み、塩化メチレンにより抽出し、飽和重曹水溶
液、水の順で洗浄した。これを硫酸マグネシウム上で乾
燥した後、減圧濃縮して得た残渣をカラムクロマトグラ
フィー(ベンゼン−アセトン、13%勾配)に付し、化
合物(3)3.4g(収率59.6%)を得た。 FAB-MS m/z:1009[M+Na]+.(1) Synthesis of Compound (8) 20 g of D-glucose was dissolved in 300 ml of dry pyridine, 34 g of triphenylmethyl chloride was added, and the mixture was stirred to dissolve and then left overnight. Acetic anhydride 30 in the reaction solution
0 ml was added and the mixture was again stirred overnight. The reaction solution was poured into ice water, extracted with methylene chloride, washed with a saturated aqueous solution of sodium hydrogencarbonate and water in this order, dried over magnesium sulfate, and concentrated under reduced pressure.
Dissolve the obtained residue in 200 ml of 70% acetic acid aqueous solution and
After refluxing for hours and filtration, the filtrate was extracted with methylene chloride, washed with a saturated aqueous solution of sodium bicarbonate and water in this order, dried over magnesium sulfate, and then concentrated under reduced pressure to obtain a residue. this,
32.07 g of compound (7) by recrystallization from diethyl ether / petroleum ether (mp. 40 ° C, yield 82.9%)
Got Compound (7) 5.4 g was dried with methylene chloride 20.
Dissolve it in ml, add 6.0 g of anhydrous calcium sulfate and 4.3 g of silver carbonate, and stir for 1 hour. Then, compound (2) 1
3.0 g was added and the mixture was stirred again overnight. The reaction solution is filtered,
The filtrate was washed with a saturated aqueous sodium hydrogen carbonate solution and water in this order, dried over magnesium sulfate, concentrated under reduced pressure, and subjected to column chromatography (CH 2 Cl 2 —MeOH, 1.0% gradient) to give compound (8) (7.3 g). (Yield 48.7%) was obtained. Compound (8): FAB-MS m / z: 989 [M + Na] + . (2) Synthesis of compound (3) Under ice cooling, 5.6 g of compound (8) was added to 150 ml of 30% hydrobromic acetic acid solution. After dissolution and stirring for 30 minutes, the reaction solution was poured into ice water, extracted with methylene chloride, and washed with a saturated aqueous sodium hydrogen carbonate solution and water in this order. This was dried over magnesium sulfate and then concentrated under reduced pressure, and the obtained residue was subjected to column chromatography (benzene-acetone, 13% gradient) to give 3.4 g of compound (3) (yield 59.6%). Obtained. FAB-MS m / z: 1009 [M + Na] + .
【0027】実施例2Example 2
【0028】[0028]
【化8】 [Chemical 8]
【0029】(1)エステルグリコシデーション 化合物(4)1.0gを乾燥塩化メチレン10mlに溶解
し、無水硫酸カルシウム7.0g及び炭酸銀1.37g
を加えて1時間撹拌した後、化合物(3)800mgを加
えて再び28時間撹拌した。反応液を濾過した後、濾液
を飽和重曹水溶液、水の順に洗浄し、硫酸マグネシウム
上で乾燥した後減圧濃縮した。得られた残渣をシリカゲ
ルカラムクロマトグラフィー(ベンゼン−アセトン、2
4.5%勾配)に付し、化合物(9)280mg(収率1
4.7%)を得た。1 H-NMR(CDCl3):表1(1) Ester glycosidation: 1.0 g of the compound (4) was dissolved in 10 ml of dry methylene chloride, 7.0 g of anhydrous calcium sulfate and 1.37 g of silver carbonate.
Was added and the mixture was stirred for 1 hour, 800 mg of the compound (3) was added, and the mixture was stirred again for 28 hours. After filtering the reaction solution, the filtrate was washed with a saturated aqueous solution of sodium hydrogencarbonate and water in this order, dried over magnesium sulfate, and then concentrated under reduced pressure. The obtained residue is subjected to silica gel column chromatography (benzene-acetone, 2
4.5% gradient), and 280 mg of compound (9) (yield 1
4.7%) was obtained. 1 H-NMR (CDCl 3 ): Table 1
【0030】(2)脱アセチル化 化合物(9)280mgを5.0%水酸化カリウムメタノ
ール溶液2mlに溶解し、室温で1時間放置し、次いで酢
酸により、中和(pH6〜7)した後、イオン交換樹脂ア
ンバーライトMB−3に付し、溶出液にピリジンを加え
て減圧濃縮し、得られた残渣をカラムクロマトグラフィ
ー(クロロホルム:メタノール:水=65:35:1
0)に付し、化合物(10)75mg(収率41.3%)
を得た。 FAB-MS m/z:1259[M+Na] +.13 C-NMR(C5D5N):表3及び表4(2) Deacetylation Compound (9) (280 mg) was dissolved in 5.0% potassium hydroxide methanol solution (2 ml), allowed to stand at room temperature for 1 hour, and then neutralized (pH 6 to 7) with acetic acid. It was attached to an ion exchange resin Amberlite MB-3, pyridine was added to the eluate and the mixture was concentrated under reduced pressure, and the obtained residue was subjected to column chromatography (chloroform: methanol: water = 65: 35: 1).
Compound (10) 75 mg (yield 41.3%)
Got FAB-MS m / z:. 1259 [M + Na] + 13 C-NMR (C 5 D 5 N): Tables 3 and 4
【0031】実施例3Example 3
【0032】[0032]
【化9】 [Chemical 9]
【0033】化合物(11)〔式(D)中、R15=−β
−D−Glc(1→6)−β−D−Glc、R16=H、
R17=−CH3〕200mgを0.1M酢酸緩衝液(pH
4.7)4mlに、溶解し、Triton X−100
0.5ml及びエムルシン(アーモンドより調製)50mg
を加え、37℃で14時間インキュベートした。反応液
にエタノール4mlを加え、80℃で5分間加温した後、
濾過し、濾液を減圧濃縮した。残渣をカラムクロマトグ
ラフィー(クロロホルム:メタノール:水=65:3
5:20〜10)に付し、化合物(12)〔式(D)
中、R15=−β−D−Glc、R16=H、R17=−CH
3〕150mg(収率88.6%)を得た。 FAB-MS m/z:919[M+Na]+.13 C-NMR(C5D5N):表3、表5Compound (11) [in the formula (D), R 15 = -β
-D-Glc (1 → 6) -β-D-Glc, R 16 = H,
R 17 = -CH 3 ] 200 mg was added to a 0.1 M acetate buffer solution (pH
4.7) Dissolve in 4 ml of Triton X-100
0.5 ml and emursin (prepared from almonds) 50 mg
Was added and incubated at 37 ° C. for 14 hours. After adding 4 ml of ethanol to the reaction mixture and heating at 80 ° C for 5 minutes,
After filtration, the filtrate was concentrated under reduced pressure. The residue was subjected to column chromatography (chloroform: methanol: water = 65: 3).
5: 20-10), the compound (12) [formula (D)
Among, R 15 = -β-D- Glc, R 16 = H, R 17 = -CH
3 ] 150 mg (yield 88.6%) was obtained. FAB-MS m / z:. 919 [M + Na] + 13 C-NMR (C 5 D 5 N): Table 3, Table 5
【0034】実施例4 化合物(13)〔式(D)中、R15=−β−D−Glc
(1→6)−β−D−Glc、R16=−β−D−Gl
c、R17=−CH3〕200mgを0.1M酢酸緩衝液(p
H4.7)4mlに溶解し、Triton X−100
0.5ml及びエムルシン(アーモンドより調製)50mg
を加え、37℃で14時間インキュベートした。反応液
にエタノール4mlを加え、80℃で5分間加温した後、
濾過し、濾液を減圧濃縮した。残渣をカラムクロマトグ
ラフィー(クロロホルム:メタノール:水=65:3
5:20〜10)に付し、化合物(14)〔式(D)
中、R15=−β−D−Glc、R16=−β−D−Gl
c、R17=−CH3〕130mg(収率75.0%)を得
た。 FAB-MS m/z:1081[M+Na]+.13 C-NMR(C5D5N):表3、表5Example 4 Compound (13) [in the formula (D), R 15 = -β-D-Glc
(1 → 6) -β-D-Glc, R 16 = -β-D-Gl
c, R 17 = -CH 3] 200mg of 0.1M acetate buffer (p
H4.7) dissolved in 4 ml, Triton X-100
0.5 ml and emursin (prepared from almonds) 50 mg
Was added and incubated at 37 ° C. for 14 hours. After adding 4 ml of ethanol to the reaction mixture and heating at 80 ° C for 5 minutes,
After filtration, the filtrate was concentrated under reduced pressure. The residue was subjected to column chromatography (chloroform: methanol: water = 65: 3).
5: 20-10), the compound (14) [formula (D)
Among, R 15 = -β-D- Glc, R 16 = -β-D-Gl
c, R 17 = -CH 3 ] 130 mg (yield 75.0%) was obtained. FAB-MS m / z:. 1081 [M + Na] + 13 C-NMR (C 5 D 5 N): Table 3, Table 5
【0035】実施例5 (1) 化合物(15)と化合物(16)のグリコシデ
ーション オレアノール酸メチル(15)1.0gを乾燥塩化メチ
レン5mlに溶解し、無水硫酸カルシウム2.0g及び炭
酸銀1.5gを加え、容器の回りを遮光して、1時間撹
拌した後、糖β−クロライド(16)7.5g、トリフ
ルオロメタンスルホン酸銀(Ag−OTf)855mg及
び1,1,3,3−テトラメチル尿素(TMU)405
μl を加え、室温で更に20時間撹拌した。反応液を濾
過した後、飽和重曹水溶液、水の順に洗浄し、硫酸マグ
ネシウムで乾燥した。濾過後、濃縮してオイル状の残渣
を得た。カラムクロマトグラフィー(ベンゼン−酢酸エ
チル、1.5%勾配)に付し、化合物(17)の粗物及
び(18)の粗物を得た。Example 5 (1) Glycosidation of compound (15) and compound (16) 1.0 g of methyl oleanolate (15) was dissolved in 5 ml of dry methylene chloride, and 2.0 g of anhydrous calcium sulfate and silver carbonate 1 were added. 0.5 g was added, and the surroundings of the container were shielded from light and stirred for 1 hour, and then 7.5 g of sugar β-chloride (16), 855 mg of silver trifluoromethanesulfonate (Ag-OTf) and 1,1,3,3- Tetramethylurea (TMU) 405
μl was added, and the mixture was further stirred at room temperature for 20 hours. The reaction solution was filtered, washed with a saturated aqueous sodium hydrogen carbonate solution and water in this order, and dried over magnesium sulfate. After filtration, it was concentrated to obtain an oily residue. Column chromatography (benzene-ethyl acetate, 1.5% gradient) gave a crude product of compound (17) and a crude product of (18).
【0036】(2)化合物(17)の粗物の脱トリクロ
ロアセチル化 化合物(17)の粗物を飽和アンモニアエーテル溶液2
0mlに溶かし、氷冷下、5分間撹拌して減圧により溶媒
を留去、各残渣をカラムクロマトグラフィー(ベンゼン
−酢酸エチル、6.0%勾配)に付し、化合物(19)
を得た。メタノールより結晶化して(19)700mg
〔収率43.4%(化合物(15)からの収率)〕を得
た。 mp.>300℃ FAB-MS m/z:781[M+Na]+.1 H-NMR(CDCl3):表6 Anal.Calcd for C43H66O11:C,68.05;H,8.76 Found C,67.84;H,8.83(2) Detrichloroacetylation of Crude of Compound (17) Crude of Compound (17) was saturated with ammonia ether solution 2
It was dissolved in 0 ml, stirred under ice cooling for 5 minutes, the solvent was distilled off under reduced pressure, and each residue was subjected to column chromatography (benzene-ethyl acetate, 6.0% gradient) to give compound (19).
Got Crystallized from methanol (19) 700 mg
[Yield 43.4% (yield from compound (15)]] was obtained. .. mp> 300 ℃ FAB- MS m / z: 781 [M + Na] + 1 H-NMR (CDCl 3): Table 6 Anal.Calcd for C 43 H 66 O 11: C, 68.05; H, 8.76 Found C, 67.84; H, 8.83
【0037】(3)化合物(19)と化合物(20)の
グリコシデーション 化合物(19)280mgを乾燥塩化メチレンに溶解し、
遮光して、無水硫酸カルシウム300mg、シアン化水銀
(II)314mg及び臭化水銀452mgを加え、1時間撹
拌した後、糖ブロム体(20)550mgを加えて再び3
日間撹拌した。反応液を濾過し、濾液を飽和重曹水溶
液、水の順に洗浄し、硫酸マグネシウム上で乾燥した
後、カラムクロマトグラフィー(ベンゼン−酢酸エチ
ル、7.0%勾配)及び高速液体クロマトグラフィー
〔ODS 10mmφ×250mm(20%水−アセト
ン)〕に付し、化合物(21)210mg(収率52.9
%)を得た。FAB-MS m/z:1097[M+Na]+.1 H-NMR(CDCl3):表8 Anal.Calcd for C56H82O20:C,62.55;H,7.69 Found C,62.35;H,7.75(3) Glycosidation of compound (19) and compound (20) 280 mg of compound (19) was dissolved in dry methylene chloride,
In the dark, 300 mg of anhydrous calcium sulfate, 314 mg of mercury (II) cyanide and 452 mg of mercury bromide were added, and the mixture was stirred for 1 hour. Then, 550 mg of sugar bromide (20) was added and the mixture was added again to 3
It was stirred for a day. The reaction solution was filtered, and the filtrate was washed with a saturated aqueous solution of sodium hydrogen carbonate and water in that order, dried over magnesium sulfate, and then subjected to column chromatography (benzene-ethyl acetate, 7.0% gradient) and high performance liquid chromatography [ODS 10 mmφ ×. 250 mm (20% water-acetone)], 210 mg of compound (21) (yield 52.9)
%) Was obtained. . FAB-MS m / z: 1097 [M + Na] + 1 H-NMR (CDCl 3): Table 8 Anal.Calcd for C 56 H 82 O 20: C, 62.55; H, 7.69 Found C, 62.35; H , 7.75
【0038】(4)化合物(21)の脱保護基反応 化合物(21)980mgを170℃でγ−コリジン2ml
に溶解した後、120℃に冷却し、ヨウ化リチウム50
0mgをあらかじめγ−コリジン2mlに加熱して溶かした
溶液を加え、再びアルゴン気流下、170℃に加熱して
2時間撹拌し、冷却後、酢酸で中和(pH6〜7)した。
次いで、減圧濃縮して得られた残渣をカラムクロマトグ
ラフィー(クロロホルム:メタノール:水=65:3
5:20〜15)に付し、本発明のグリコシド(22)
340mg(収率46.9%)を得た。 [α]D 20-32.4°(c=1.85、ピリジン) FAB-MS m/z:817[M+Na]+.13 C-NMR(C5D5N):表10(4) Deprotection group reaction of compound (21) 980 mg of compound (21) at 170 ° C. in 2 ml of γ-collidine
And then cooled to 120 ° C. to obtain lithium iodide 50
A solution prepared by heating 0 mg of 2 mg of γ-collidine in advance was added, heated again to 170 ° C. under an argon stream and stirred for 2 hours, cooled, and then neutralized with acetic acid (pH 6 to 7).
Then, the residue obtained by concentration under reduced pressure was subjected to column chromatography (chloroform: methanol: water = 65: 3).
5: 20-15), and the glycoside (22) of the present invention.
340 mg (yield 46.9%) was obtained. [α] D 20 -32.4 ° ( c = 1.85, pyridine) FAB-MS m / z: . 817 [M + Na] + 13 C-NMR (C 5 D 5 N): Table 10
【0039】実施例6 (1)化合物(18)の粗物の脱トリクロロアセチル化Example 6 (1) Detrichloroacetylation of crude compound (18)
【0040】[0040]
【化10】 [Chemical 10]
【0041】化合物(18)の粗物を飽和アンモニアエ
ーテル溶液20mlに溶かし、氷冷下、5分間撹拌した
後、減圧により溶媒を留去した。各残渣をカラムクロマ
トグラフィー(ベンゼン−酢酸エチル、6.0%勾配)
に付し、メタノールより結晶化して化合物(23)〔式
(E)中、R18=OAc、R19=R21=H、R20=CH
2OAc〕630mg〔収率39.1%(化合物(15)
からの収率)〕を得た。 mp.>300℃ FAB-MS m/z:781[M+Na]+.1 H-NMR(CDCl3):表6 Anal.Calcd for C43H66O11:C,68.05;H,8.76 Found C,67.69;H,8.91The crude product of compound (18) was saturated with ammonia.
It was dissolved in 20 ml of ether solution and stirred for 5 minutes under ice cooling.
After that, the solvent was distilled off under reduced pressure. Column chromatograph each residue
Tography (benzene-ethyl acetate, 6.0% gradient)
And crystallized from methanol to give compound (23) [formula
(E) Medium, R18= OAc, R19= Rtwenty one= H, R20= CH
2OAc] 630 mg [yield 39.1% (compound (15)
From the above)) was obtained. mp.> 300 ℃ FAB-MS m / z: 781 [M + Na]+.1 H-NMR (CDCl3): Table 6 Anal.Calcd for C43H66O11: C, 68.05; H, 8.76 Found C, 67.69; H, 8.91
【0042】(2)化合物(23)と化合物(20)の
グリコシデーション(2) Glycosidation of compound (23) and compound (20)
【0043】[0043]
【化11】 [Chemical 11]
【0044】化合物(23)472mgを乾燥塩化メチレ
ンに溶解し、遮光して、無水硫酸カルシウム300mg、
シアン化水銀(II)360mg及び臭化水銀(II)490
mgを加え、1時間撹拌した後、糖ブロム体(20)76
0mgを加えて再び1日間撹拌した。反応液を濾過した
後、濾液を飽和重曹水溶液、水の順に洗浄し、硫酸マグ
ネシウム上で乾燥した後、カラムクロマトグラフィー
(ベンゼン−酢酸エチル、10.0%勾配)及び高速液
体クロマトグラフィー〔ODS 10mmφ×250mm
(20%水−アセトン)〕に付し、本発明のグリコシド
(24)〔式(F)中、R22=Ac、R23=OAc、R
24=H、R25=CH2OAc、R26=CH3〕350mg
(収率52.3%)を得た。 FAB-MS m/z:1097[M+Na]+.1 H-NMR(CDCl3):表8 Anal.Calcd for C56H82O20:C,62.55;H,7.69 Found C,62.41;H,7.87472 mg of the compound (23) was dissolved in dry methylene chloride, shielded from light and 300 mg of anhydrous calcium sulfate,
Mercury (II) cyanide 360 mg and mercury (II) bromide 490
After adding mg and stirring for 1 hour, sugar bromide (20) 76
0 mg was added and the mixture was stirred again for 1 day. After filtering the reaction solution, the filtrate was washed with a saturated aqueous solution of sodium bicarbonate and water in that order, dried over magnesium sulfate, and then subjected to column chromatography (benzene-ethyl acetate, 10.0% gradient) and high performance liquid chromatography [ODS 10 mmφ. × 250 mm
(20% water-acetone)], and the glycoside (24) of the present invention [in the formula (F), R 22 = Ac, R 23 = OAc, R
24 = H, R 25 = CH 2 OAc, R 26 = CH 3 ] 350mg
(Yield 52.3%) was obtained. . FAB-MS m / z: 1097 [M + Na] + 1 H-NMR (CDCl 3): Table 8 Anal.Calcd for C 56 H 82 O 20: C, 62.55; H, 7.69 Found C, 62.41; H , 7.87
【0045】(3)化合物(24)の脱保護基反応 化合物(24)115mgを170℃でγ−コリジン2ml
に溶解し、120℃に冷却して、ヨウ化リチウム500
mgをあらかじめγ−コリジン2mlに加熱して溶かした溶
液を加え、再びアルゴン気流下、170℃で2時間撹拌
し冷却後、酢酸で中和(pH6〜7)した。次いで、減圧
濃縮して得た残渣をカラムクロマトグラフィー(クロロ
ホルム:メタノール:水=65:35:20〜15)に
付し、本発明のグリコシド(25)〔式(F)中、R22
=R24=R26=H、R23=OH、R25=CH2OH〕6
3mg(収率74.1%)を得た。 FAB-MS m/z:817[M+Na]+.13 C-NMR(C5D5N):表10(3) Deprotection group reaction of compound (24) 115 mg of compound (24) at 170 ° C. in 2 ml of γ-collidine
Lithium iodide 500
A solution prepared by previously heating and dissolving 2 mg of γ-collidine in 2 ml was added, the mixture was stirred again at 170 ° C. for 2 hours under an argon stream, cooled, and then neutralized with acetic acid (pH 6 to 7). Then, the residue obtained by concentration under reduced pressure was subjected to column chromatography (chloroform: methanol: water = 65: 35: 20-15) to give the glycoside (25) of the present invention [R 22 in the formula (F)].
= R 24 = R 26 = H, R 23 = OH, R 25 = CH 2 OH] 6
3 mg (yield 74.1%) was obtained. FAB-MS m / z:. 817 [M + Na] + 13 C-NMR (C 5 D 5 N): Table 10
【0046】実施例7 (1)化合物(15)と化合物(26)のグリコシデー
ションExample 7 (1) Glycosidation of compound (15) and compound (26)
【0047】[0047]
【化12】 [Chemical 12]
【0048】オレアノール酸メチル(15)2.0gを
乾燥塩化メチレン3mlに溶解し、無水硫酸カルシウム
1.5g及び炭酸銀1.1gを加え、容器の回りを遮光
して、1時間撹拌した後、糖β−クロライド(26)1
8.0g、トリフルオロメタンスルホン酸銀(Ag−O
Tf)6.6g及び1,1,3,3−テトラメチル尿素
(TMU)3.7mlを加え、室温で3日間撹拌した。反
応液を濾過した後、飽和重曹水溶液、水の順に洗浄し、
硫酸マグネシウム上で乾燥した。濾過後、濃縮してオイ
ル状の残渣を得た。残渣はカラムクロマトグラフィー
(ベンゼン−アセトン、0.6%勾配)に付し、化合物
(27)の粗物〔式(G)中、R27=OAc、R28=
H、R29=COOCH3、R30=COCCl3〕及び(2
8)の粗物〔式(E)中、R18=OAc、R19=H、R
20=COOCH3、R21=COCCl3〕を得た。2.0 g of methyl oleanolate (15) was dissolved in 3 ml of dry methylene chloride, 1.5 g of anhydrous calcium sulfate and 1.1 g of silver carbonate were added, and the surroundings of the container were shielded from light and stirred for 1 hour. Sugar β-chloride (26) 1
8.0 g, silver trifluoromethanesulfonate (Ag-O
Tf) (6.6 g) and 1,1,3,3-tetramethylurea (TMU) (3.7 ml) were added, and the mixture was stirred at room temperature for 3 days. After filtering the reaction solution, it was washed with a saturated aqueous sodium hydrogen carbonate solution and water in this order,
Dry over magnesium sulfate. After filtration, it was concentrated to obtain an oily residue. The residue was subjected to column chromatography (benzene-acetone, 0.6% gradient) to give a crude product of compound (27) [in the formula (G), R 27 = OAc, R 28 =
H, R 29 = COOCH 3, R 30 = COCCl 3 ] and (2
8) Crude product [in the formula (E), R 18 = OAc, R 19 = H, R
20 = COOCH 3 , R 21 = COCCl 3 ].
【0049】(2)化合物(27)の粗物の脱トリクロ
ロアセチル化 化合物(27)を飽和アンモニアエーテル溶液10mlに
溶解し、氷冷下、5分間撹拌し、減圧下溶媒を留去し
た。得られた残渣をカラムクロマトグラフィー(ベンゼ
ン−酢酸エチル、6.0%勾配)に付し、オイル状の化
合物(29)〔式(G)中、R27=OAc、R28=H、
R29=COOCH3、R30=H〕1.42g〔収率4
4.9%(化合物(15)からの収率)〕を得た。 FAB-MS m/z:767[M+Na]+.1 H-NMR(CDCl3):表7 Anal.Calcd for C42H64O11:C,67.72;H,8.66 Found C,67.41;H,8.83(2) Detrichloroacetylation of crude compound (27) The compound (27) was dissolved in 10 ml of a saturated ammonia ether solution and stirred for 5 minutes under ice cooling, and the solvent was distilled off under reduced pressure. The obtained residue was subjected to column chromatography (benzene-ethyl acetate, 6.0% gradient) to give an oily compound (29) [in the formula (G), R 27 = OAc, R 28 = H,
R 29 = COOCH 3 , R 30 = H] 1.42 g [yield 4
4.9% (yield from compound (15))] was obtained. . FAB-MS m / z: 767 [M + Na] + 1 H-NMR (CDCl 3): Table 7 Anal.Calcd for C 42 H 64 O 11: C, 67.72; H, 8.66 Found C, 67.41; H , 8.83
【0050】(3)化合物(29)と化合物(20)の
グリコシデーション(3) Glycosidation of compound (29) and compound (20)
【0051】[0051]
【化13】 [Chemical 13]
【0052】化合物(29)350mgの乾燥塩化メチレ
ン2ml溶液に、無水硫酸カルシウム200mg、シアン化
水銀(II)238mg及び臭化水銀(II)336mgを加
え、1時間撹拌した後、糖ブロム体(20)700mgを
加え、4日間撹拌した。反応液を濾過した後、濾液を飽
和重曹水溶液、水の順に洗浄し、硫酸マグネシウム上で
乾燥した後、減圧濃縮して得た残渣をカラムクロマトグ
ラフィー(ベンゼン−酢酸エチル、6.0%勾配)に付
し、本発明のグリコシド(30)〔式(H)中、R31=
Ac、R32=OAc、R33=H、R34=COOCH3、
R35=CH3〕270mg(収率54.2%)を得た。 FAB-MS m/z:1083[M+Na]+.1 H-NMR(CDCl3):表9 Anal.Calcd for C55H80O20:C,62.25;H,7.60 Found C,62.13;H,7.78To a solution of 350 mg of the compound (29) in 2 ml of dry methylene chloride, 200 mg of anhydrous calcium sulfate, 238 mg of mercury (II) cyanide and 336 mg of mercury (II) bromide were added, and the mixture was stirred for 1 hour. ) 700 mg was added and stirred for 4 days. After filtering the reaction solution, the filtrate was washed with a saturated aqueous solution of sodium bicarbonate and water in this order, dried over magnesium sulfate, and then concentrated under reduced pressure to obtain a residue, which was subjected to column chromatography (benzene-ethyl acetate, 6.0% gradient). The glycoside (30) of the present invention [in the formula (H), R 31 =
Ac, R 32 = OAc, R 33 = H, R 34 = COOCH 3 ,
R 35 = CH 3 ] 270 mg (yield 54.2%) was obtained. . FAB-MS m / z: 1083 [M + Na] + 1 H-NMR (CDCl 3): Table 9 Anal.Calcd for C 55 H 80 O 20: C, 62.25; H, 7.60 Found C, 62.13; H , 7.78
【0053】(4)化合物(30)の脱保護基反応 化合物(30)150mgを5.0%水酸化カリウム溶液
2ml(エタノール:水=1:1)に溶かし、5時間還流
した。反応後、酢酸で中和し、減圧濃縮し、残渣を17
0℃でγ−コリジン2mlに溶解し、120℃に冷却した
後、ヨウ化リチウム500mgをあらかじめγ−コリジン
2mlに加熱しておいた溶液を加え、再びアルゴン気流
下、170℃で2時間撹拌し冷却後、酢酸で中和(pH6
〜7)した。次いで、減圧濃縮し、得られた残渣をカラ
ムクロマトグラフィー(クロロホルム:メタノール:水
=65:35:20〜10)に付し、本発明のグリコシ
ド(31)〔式(H)中、R31=R33=R35=H、R32
=OH、R34=COOH〕100mg(収率85.5%)
を得た。 [α]D 20+41.0°(c=1.34,ピリジン) FAB-MS m/z:853[M-1+2Na]+.13 C-NMR(C5D5N):表10(4) Deprotection group reaction of compound (30) 150 mg of compound (30) was dissolved in 2 ml of 5.0% potassium hydroxide solution (ethanol: water = 1: 1) and refluxed for 5 hours. After the reaction, neutralize with acetic acid and concentrate under reduced pressure.
After dissolving in 2 ml of γ-collidine at 0 ° C and cooling to 120 ° C, a solution of 500 mg of lithium iodide preheated to 2 ml of γ-collidine was added, and the mixture was stirred again at 170 ° C for 2 hours under an argon stream. After cooling, neutralize with acetic acid (pH 6
~ 7) did. Then, the mixture was concentrated under reduced pressure, and the obtained residue was subjected to column chromatography (chloroform: methanol: water = 65: 35: 20-10) to give the glycoside (31) of the present invention [in the formula (H), R 31 = R 33 = R 35 = H, R 32
= OH, R 34 = COOH] 100 mg (yield 85.5%)
Got [α] D 20 + 41.0 ° (c = 1.34, pyridine) FAB-MS m / z: . 853 [M-1 + 2Na] + 13 C-NMR (C 5 D 5 N): Table 10
【0054】実施例8 (1)化合物(28)の粗物の脱トリクロロアセチル化 実施例7(1)で得た化合物(28)の粗物を飽和アン
モニアエーテル溶液10mlに溶解し氷冷下、5分間撹拌
して減圧下により溶媒を留去して得た残渣をカラムクロ
マトグラフィー(ベンゼン−酢酸エチル、6.0%勾
配)に付し、オイル状の化合物(32)〔式(E)中、
R18=OAc、R19=R21=H、R20=COOCH3〕
730mg〔収率23.3%(化合物(19)からの収
率)〕を得た。 FAB-MS m/z:767[M+Na]+.1 H-NMR(CDCl3):表7 Anal.Calcd for C42H64O11:C,67.72;H,8.66 Found C,67.29;H,8.72Example 8 (1) Detrichloroacetylation of Crude Compound (28) The crude compound (28) obtained in Example 7 (1) was dissolved in 10 ml of a saturated ammonia ether solution, and the mixture was cooled with ice. The residue obtained by stirring for 5 minutes and distilling off the solvent under reduced pressure was subjected to column chromatography (benzene-ethyl acetate, 6.0% gradient) to give an oily compound (32) [in formula (E) ,
R 18 = OAc, R 19 = R 21 = H, R 20 = COOCH 3 ]
730 mg [yield 23.3% (yield from compound (19)]] were obtained. . FAB-MS m / z: 767 [M + Na] + 1 H-NMR (CDCl 3): Table 7 Anal.Calcd for C 42 H 64 O 11: C, 67.72; H, 8.66 Found C, 67.29; H , 8.72
【0055】(2)化合物(32)と化合物(20)の
グリコシデーション 化合物(32)675mgを乾燥塩化メチレン18mlに溶
解し、無水硫酸カルシウム600mg、シアン化水銀(I
I)457mg及び臭化水銀(II)635mgを加え、室温
で1時間撹拌した後、化合物(20)1.4gを加えて
更に5日間撹拌した。反応液を濾過した後、濾液を氷水
に注ぎ込み、塩化メチレンで抽出した。抽出液を飽和炭
酸水素カリウム水溶液、水の順で洗浄した後、硫酸マグ
ネシウムで乾燥した。濾過後、濃縮して得た残渣をカラ
ムクロマトグラフィー(ベンゼン−酢酸エチル、12%
勾配)に付し、次いで分取高速液体クロマトグラフィー
(ODS−4251、メタノール、1ml/min、35
℃)で精製して本発明のグリコシド(33)〔式(F)
中、R22=Ac、R23=OAc、R24=H、R25=CO
OCH3、R26=CH3〕740mgを得た。(収率77.
0%)。 FAB-MS m/z:1083[M+Na]+.1 H-NMR(CDCl3):表9 Anal.Calcd for C55H80O20・1/2H2O:C,61.72;H,7.63. Found C,61.73;H,7.50(2) Glycosidation of compound (32) and compound (20) 675 mg of compound (32) was dissolved in 18 ml of dry methylene chloride, and 600 mg of anhydrous calcium sulfate and mercury cyanide (I
457 mg of I) and 635 mg of mercury (II) bromide were added, and the mixture was stirred at room temperature for 1 hour, 1.4 g of compound (20) was added, and the mixture was further stirred for 5 days. After filtering the reaction solution, the filtrate was poured into ice water and extracted with methylene chloride. The extract was washed with a saturated aqueous solution of potassium hydrogen carbonate and water in this order, and then dried over magnesium sulfate. After filtration, the residue obtained by concentration is subjected to column chromatography (benzene-ethyl acetate, 12%
Gradient) followed by preparative high performance liquid chromatography (ODS-4251, methanol, 1 ml / min, 35
Glycoside (33) of the present invention [formula (F)
Medium, R 22 = Ac, R 23 = OAc, R 24 = H, R 25 = CO
740 mg of OCH 3 , R 26 ═CH 3 ]. (Yield 77.
0%). . FAB-MS m / z: 1083 [M + Na] + 1 H-NMR (CDCl 3): Table 9 Anal.Calcd for C 55 H 80 O 20 · 1 / 2H 2 O: C, 61.72; H, 7.63 .Found C, 61.73; H, 7.50
【0056】(3)化合物(33)の脱保護基反応 化合物(33)670mgを、実施例7(4)と同様に処
理して脱アセチル体354mgを得た。このものをγ−コ
リジン7mlに溶解し、ヨウ化リチウム500mgを予めγ
−コリンジ2mlに加熱して溶かした溶液を加え、アルゴ
ン気流下、160℃で12.5時間撹拌した。反応液を
酢酸で中和した後、減圧濃縮して残渣を得た。この残渣
をカラムクロマトグラフィー(クロロホルム:メタノー
ル:水=63:35:20〜10)に付し、本発明のグ
リコシド(34)〔式(F)中、R22=R24=R26=
H、R23=OH、R25=COOH〕193.6mg(収率
37.91%)を得た。 FAB-MS m/z:853[M-1+2Na]+.13 C-NMR(C5D5N):表10(3) Deprotection group reaction of compound (33) 670 mg of compound (33) was treated in the same manner as in Example 7 (4) to obtain 354 mg of deacetylated product. This product was dissolved in 7 ml of γ-collidine, and 500 mg of lithium iodide was previously added to γ.
-Adding the solution which was heated to 2 ml of cholinedi and dissolved, it was stirred at 160 ° C for 12.5 hours under an argon stream. The reaction solution was neutralized with acetic acid and then concentrated under reduced pressure to obtain a residue. The residue was subjected to column chromatography (chloroform: methanol: water = 63: 35: 20-10) to give the glycoside (34) of the present invention [in the formula (F), R 22 = R 24 = R 26 =
H, R 23 = OH, R 25 = COOH] 193.6 mg (yield 37.91%) was obtained. FAB-MS m / z:. 853 [M-1 + 2Na] + 13 C-NMR (C 5 D 5 N): Table 10
【0057】[0057]
【化14】 [Chemical 14]
【0058】実施例9 (1)化合物(15)と化合物(35)のグリコシデー
ション オレアノール酸メチル(15)5.0gの乾燥塩化メチ
レン10ml溶液に、無水硫酸カルシウム5.0g及び炭
酸銀2.8gを加え、容器の回りを遮光して、1時間撹
拌した後、糖β−クロライド(35)27.0g、トリ
フルオロメタンスルホン酸銀(Ag−OTf)13.9
g及び1,1,3,3−テトラメチル尿素(TMU)
7.6mlを加え、室温で4日間撹拌した。反応液を濾過
し、飽和重曹水溶液、水の順に洗浄し、硫酸マグネシウ
ムで乾燥した。濾過後、濃縮してオイル状の残渣を得
た。残渣はカラムクロマトグラフィー(ベンゼン−アセ
トン、4.0%勾配)に付し、化合物(36)の粗物
〔式(G)中、R27=H、R28=OAc、R29=CH2
OAc、R30=COCCl3〕及び化合物(37)の粗
物〔式(E)中、R18=H、R19=OAc、R20=CH
2OAc、R21=COCCl3〕を得た。Example 9 (1) Glycosidation of compound (15) and compound (35) 5.0 g of methyl oleanolate (15) in 10 ml of dry methylene chloride was added to 5.0 g of anhydrous calcium sulfate and silver carbonate 2. After adding 8 g and shielding from light around the container and stirring for 1 hour, 27.0 g of sugar β-chloride (35) and silver trifluoromethanesulfonate (Ag-OTf) 13.9.
g and 1,1,3,3-tetramethylurea (TMU)
7.6 ml was added, and the mixture was stirred at room temperature for 4 days. The reaction solution was filtered, washed with a saturated aqueous sodium hydrogen carbonate solution and water in this order, and dried over magnesium sulfate. After filtration, it was concentrated to obtain an oily residue. The residue was subjected to column chromatography (benzene-acetone, 4.0% gradient) to give a crude product of compound (36) [in the formula (G), R 27 = H, R 28 = OAc, R 29 = CH 2].
OAc, R 30 = COCCl 3 ] and a crude compound (37) [in the formula (E), R 18 = H, R 19 = OAc, R 20 = CH].
2 OAc, R 21 = COCCl 3 ].
【0059】(2)化合物(36)の粗物の脱トリクロ
ロアセチル化 化合物(36)の粗物を飽和アンモニアエーテル溶液1
0mlに溶解し、氷冷下、5分間撹拌し、減圧により溶媒
を留去した。残渣をカラムクロマトグラフィー(ベンゼ
ン−酢酸エチル、6.0%勾配)に付し、オイル状の化
合物(38)〔式(G)中、R27=H、R28=OAc、
R29=CH2OAc、R30=H〕3.86g〔収率4
7.9%(化合物(15)からの収率)〕を得た。 FAB-MS m/z:781[M+Na]+.1 H-NMR(CDCl3):表6 Anal.Calcd for C43H66O11:C,68.05;H,8.76 Found C,67.92;H,8.82(2) Detrichloroacetylation of Crude of Compound (36) Crude of Compound (36) was added to saturated ammonia ether solution 1
It was dissolved in 0 ml, stirred for 5 minutes under ice cooling, and the solvent was distilled off under reduced pressure. The residue was subjected to column chromatography (benzene-ethyl acetate, 6.0% gradient) to give an oily compound (38) [in the formula (G), R 27 = H, R 28 = OAc,
R 29 = CH 2 OAc, R 30 = H] 3.86 g [yield 4
7.9% (yield from compound (15))] was obtained. . FAB-MS m / z: 781 [M + Na] + 1 H-NMR (CDCl 3): Table 6 Anal.Calcd for C 43 H 66 O 11: C, 68.05; H, 8.76 Found C, 67.92; H , 8.82
【0060】(3)化合物(38)と化合物(20)の
グリコシデーション 化合物(38)1.0gを乾燥塩化メチレンに溶解し、
無水硫酸カルシウム1.0g、シアン化水銀(II)6.
3g及び臭化水銀(II)9.1gを加えて1時間撹拌し
た後、糖ブロム体(20)11.6gを加えて再び3日
間撹拌した。反応液を濾過した後、濾液を飽和重曹水溶
液、水の順に洗浄し、硫酸マグネシウム上で乾燥した
後、減圧濃縮で得た残渣をカラムクロマトグラフィー
(ベンゼン−酢酸エチル、10.0%勾配)及び高速液
体クロマトグラフィー(ODS10mmφ×250mm(メ
タノール)〕に付し、オイル状の本発明グリコシド(3
9)〔式(H)中、R31=Ac、R32=H、R33=OA
c、R34=CH2OAc、R35=CH3〕1.1g(収率
77.6%)を得た。 FAB-MS m/z:1097[M+Na]+.1 H-NMR(CDCl3):表8 Anal.Calcd for C55H82O20:C,62.55;H,7.69 Found C,62.43;H,7.79(3) Glycosidation of compound (38) and compound (20) 1.0 g of compound (38) was dissolved in dry methylene chloride,
Anhydrous calcium sulfate 1.0 g, mercury (II) cyanide 6.
After 3 g and 9.1 g of mercury (II) bromide were added and stirred for 1 hour, 11.6 g of sugar bromide (20) was added and stirred again for 3 days. After filtering the reaction solution, the filtrate was washed with a saturated aqueous solution of sodium bicarbonate and water in this order, dried over magnesium sulfate, and then the residue obtained by concentration under reduced pressure was subjected to column chromatography (benzene-ethyl acetate, 10.0% gradient) and Subjected to high performance liquid chromatography (ODS 10 mmφ × 250 mm (methanol)], the glycoside of the present invention (3
9) [in the formula (H), R 31 = Ac, R 32 = H, R 33 = OA
c, to give R 34 = CH 2 OAc, R 35 = CH 3 ] 1.1g of (77.6% yield). . FAB-MS m / z: 1097 [M + Na] + 1 H-NMR (CDCl 3): Table 8 Anal.Calcd for C 55 H 82 O 20: C, 62.55; H, 7.69 Found C, 62.43; H , 7.79
【0061】(4)化合物(39)の脱保護基反応 化合物(39)1.1gを5.0%水酸化カリウム溶液
5ml(エタノール:水=1:1)で5時間還流し、冷却
後、酢酸で中和し、減圧濃縮して得た残渣を170℃で
γ−コリジン10mlに溶解し、120℃に冷却した後、
ヨウ化リチウム500mgをあらかじめγ−コリジン2ml
に加熱して溶かした溶液を加え、再びアルゴン気流下、
170℃で2時間撹拌し、冷却後、酢酸で中和(pH6〜
7)した。次いで、減圧濃縮して得られた残渣をカラム
クロマトグラフィー(クロロホルム:メタノール:水=
63:35:20〜15)に付し、本発明グリコシド
(40)〔式(H)中、R31=R32=R35=H、R33=
OH、R34=CH2OH〕490mg(収率60.3%)
を得た。 [α]D 20+7.3°(c=2.06,ピリジン) FAB-MS m/z:817[M+Na]+.13 C-NMR(C5D5N):表10(4) Deprotection group reaction of compound (39) 1.1 g of compound (39) was refluxed for 5 hours with 5 ml of 5.0% potassium hydroxide solution (ethanol: water = 1: 1), and after cooling, The residue obtained by neutralizing with acetic acid and concentrating under reduced pressure was dissolved in 10 ml of γ-collidine at 170 ° C and cooled to 120 ° C.
Lithium iodide (500 mg) was previously mixed with γ-collidine (2 ml).
Add the solution that was heated and melted, and again under argon flow,
Stir at 170 ° C for 2 hours, cool, and then neutralize with acetic acid (pH 6-
7) I did. Then, the residue obtained by concentration under reduced pressure was subjected to column chromatography (chloroform: methanol: water =
63: 35: 20-15), the glycoside (40) of the present invention [in the formula (H), R 31 = R 32 = R 35 = H, R 33 =
OH, R 34 = CH 2 OH] 490 mg (yield 60.3%)
Got [α] D 20 + 7.3 ° (c = 2.06, pyridine) FAB-MS m / z: . 817 [M + Na] + 13 C-NMR (C 5 D 5 N): Table 10
【0062】実施例10 (1)化合物(41)の合成 実施例9(1)で得られた化合物(37)の粗物を氷冷
下、飽和アンモニアエーテル溶液10mlに溶解し、5分
間攪拌する。反応液を減圧濃縮し残渣をシリカゲルカラ
ムクロマトグラフィー(ベンゼン−酢酸エチル、6.0
%勾配)に付し、オイル状の化合物(41)〔式(E)
中、R18=H、R19=OAc、R20=CH2OAc、R
21=OH〕3.86g〔収率47.9%(化合物(1
5)からの収率)〕を得た。 FAB-MS m/z:781[M+Na]+. Anal.Calcd for C43H66O11:C,68.05;H,8.76 Found C,67.92;H,8.82Example 10 (1) Synthesis of compound (41) The crude product of compound (37) obtained in Example 9 (1) was dissolved in 10 ml of saturated ammonia ether solution under ice cooling and stirred for 5 minutes. . The reaction solution was concentrated under reduced pressure and the residue was subjected to silica gel column chromatography (benzene-ethyl acetate, 6.0).
% Gradient) to give an oily compound (41) [formula (E)
Medium, R 18 = H, R 19 = OAc, R 20 = CH 2 OAc, R
21 = OH] 3.86 g [yield 47.9% (compound (1
The yield from 5))] was obtained. FAB-MS m / z: 781 [M + Na] + .Ana.Calcd for C 43 H 66 O 11 : C, 68.05; H, 8.76 Found C, 67.92; H, 8.82
【0063】(2)化合物(41)と化合物(20)の
グリコシデーション 化合物(41)1.2gを乾燥塩化メチレンに溶解し、
無水硫酸カルシウム1.0g、シアン化水銀(II)4.
9g及び、臭化水銀(II)7.3gを加え、1時間攪拌
した後、糖ブロム体(20)8.8gを加えて再び2日
間攪拌した。反応液を濾過した後、濾液を飽和重曹水溶
液、水の順に洗浄、硫酸マクネシウム上で乾燥した後、
減圧濃縮して得た残渣をカラムクロマトグラフィー(ベ
ンゼン−酢酸エチル、12.0%勾配)及び、高速液体
クロマトグラフィーHPLC〔ODS 10mmφ×25
0mm(メタノール)〕に付し、オイル状の本発明グリコ
シド(42)〔式(F)中、R22=Ac、R23=H、R
24=OAc、R25=CH2OAc、R26=CH3 〕99
0mg(収率58.2%)を得た。 FAB-MS m/z:1097[M+Na]+.1 H-NMR(CDCl3):表9 Anal.Calcd for C56H82O20:C,62.55;H,7.69 Found C,62.33;H,7.88(2) Glycosidation of compound (41) and compound (20) 1.2 g of compound (41) was dissolved in dry methylene chloride,
Anhydrous calcium sulfate 1.0 g, mercury (II) cyanide 4.
After adding 9 g and 7.3 g of mercury (II) bromide and stirring for 1 hour, 8.8 g of sugar bromide (20) was added and the mixture was stirred again for 2 days. After filtering the reaction solution, the filtrate was washed with a saturated aqueous sodium hydrogen carbonate solution and water in this order and dried over magnesium sulfate,
The residue obtained by concentration under reduced pressure was subjected to column chromatography (benzene-ethyl acetate, 12.0% gradient) and high performance liquid chromatography HPLC [ODS 10 mmφ × 25.
0 mm (methanol)], and an oily glycoside (42) of the present invention [in the formula (F), R 22 = Ac, R 23 = H, R
24 = OAc, R 25 = CH 2 OAc, R 26 = CH 3 ] 99
0 mg (yield 58.2%) was obtained. . FAB-MS m / z: 1097 [M + Na] + 1 H-NMR (CDCl 3): Table 9 Anal.Calcd for C 56 H 82 O 20: C, 62.55; H, 7.69 Found C, 62.33; H , 7.88
【0064】(2)化合物(42)の脱保護基反応 化合物(42)990mgを5.0%水酸化カリウム溶液
(エタノール:水=1:1)5mlで5時間還流した後、
酢酸で中和し、減圧濃縮した。残渣を170℃でγ−コ
リジン8mlに溶解し、120℃に冷却した後、ヨウ化リ
チウム500mgをあらかじめγ−コリジンに加熱して溶
かした溶液2mlを加え、再びアルゴン気流下、170℃
に加熱して2時間攪拌し、冷却後、酢酸で中和(pH6〜
7)した。次いで、減圧濃縮して得た残渣をカラムクロ
マトグラフィー(クロロホルム:メタノール:水=6
5:35:20〜15)に付し、本発明グリコシド(4
3)〔式(F)中、R22=R23=R26=H、R24=O
H、R25=CH2OH〕420mg(収率57.4%)を
得た。 [α]D 20+75.0°(c=1.40,ピリジン) FAB-MS m/z:817[M+Na]+.1 H-NMR(C5D5N): 表10(2) Deprotection group reaction of compound (42) 990 mg of compound (42) was refluxed with 5 ml of 5.0% potassium hydroxide solution (ethanol: water = 1: 1) for 5 hours,
It was neutralized with acetic acid and concentrated under reduced pressure. The residue was dissolved in 8 ml of γ-collidine at 170 ° C., cooled to 120 ° C., 2 ml of a solution prepared by previously heating 500 mg of lithium iodide to γ-collidine was added, and the mixture was again heated to 170 ° C. in an argon stream.
Heat to room temperature and stir for 2 hours. After cooling, neutralize with acetic acid (pH 6-
7) I did. Then, the residue obtained by concentration under reduced pressure was subjected to column chromatography (chloroform: methanol: water = 6).
5: 35: 20-15), the glycoside of the present invention (4
3) [In the formula (F), R 22 = R 23 = R 26 = H, R 24 = O
H, R 25 = CH 2 OH] 420 mg (yield 57.4%) was obtained. [α] D 20 + 75.0 ° (c = 1.40, pyridine) FAB-MS m / z: . 817 [M + Na] + 1 H-NMR (C 5 D 5 N): Table 10
【0065】[0065]
【表1】 [Table 1]
【0066】[0066]
【表2】 [Table 2]
【0067】[0067]
【表3】 [Table 3]
【0068】[0068]
【表4】 [Table 4]
【0069】[0069]
【表5】 [Table 5]
【0070】[0070]
【表6】 [Table 6]
【0071】[0071]
【表7】 [Table 7]
【0072】[0072]
【表8】 [Table 8]
【0073】[0073]
【表9】 [Table 9]
【0074】[0074]
【表10】 [Table 10]
【0075】試験例 実施例で得られた本発明のグリコシドについて、以下の
ようにして、薬理活性を調べた。すなわち、セグレンら
の方法〔Methods in Cell Bio
l.,28,432,(1970)〕によりラットの肝
臓から単離した肝細胞を2×106個/mlに調整し、こ
れを50%四塩化炭素揮発充満させたコルベン内に入
れ、インキュベートして実験的肝炎を惹起させた後、各
サポニンの1mgを0.1mlのハンクス液に溶かした溶液
及びコントロール(C)にはハンクス液0.1mlのみを
加え、37℃で1時間インキュベートした。ついで、反
応懸濁液を遠心分離(10000rpm×19分)に付
し、上清液のアスパラギン酸トランスフェラーゼ(AS
T)、アラニントランスフェラーゼ(ALT)活性を測
定した。なお、本実験は肝炎にかかっている肝細胞から
はAST、ALT等の酵素が多く遊離してくることを利
用したものであり、AST、ALT活性の小さいものが
肝庇護効果が大きいことになる。各化合物及びコントロ
ールは各々10検体ずつを用いて行い、データはその平
均値で示した。結果を図1に示す。Test Example The glycosides of the present invention obtained in the examples were examined for pharmacological activity as follows. That is, the method of Segren et al. [Methods in Cell Bio
l. , 28, 432, (1970)], the hepatocytes isolated from rat liver were adjusted to 2 × 10 6 cells / ml, and the hepatocytes were placed in a Kolben filled with 50% carbon tetrachloride volatilized and incubated. After inducing experimental hepatitis, only 0.1 ml of Hanks 'solution was added to a solution prepared by dissolving 1 mg of each saponin in 0.1 ml of Hanks' solution and control (C), and incubated at 37 ° C. for 1 hour. Then, the reaction suspension was subjected to centrifugation (10000 rpm × 19 minutes), and aspartate transferase (AS
T), alanine transferase (ALT) activity was measured. This experiment uses the fact that a large amount of enzymes such as AST and ALT are released from hepatocytes suffering from hepatitis, and those with small AST and ALT activities have a great effect on liver protection. . 10 compounds were used for each compound and control, and the data are shown as the average value. The results are shown in Fig. 1.
【図面の簡単な説明】[Brief description of drawings]
【図1】試験例において、本発明化合物のAST、AL
T活性を測定した結果を示す図である。FIG. 1 shows AST and AL of compounds of the present invention in test examples.
It is a figure which shows the result of having measured T activity.
Claims (2)
シ基が低級アルカノイル基で保護されていてもよい単糖
残基、二糖残基若しくは三糖残基を示し、R2 は水素原
子、メチル基又はヒドロキシメチル基を示し、R3 及び
R8 はヒドロキシ基、−CH2OR3′又は−COO
R8′(ここでR3′は水素原子又は低級アルカノイル基
を示し、R8′は水素原子又は低級アルキル基を示す)
を示し、R4 及びR5 のいずれか一方、R6 及びR7 の
いずれか一方又はR9 及びR10のいずれか一方は水素原
子を、他方はヒドロキシ基又は低級アルカノイルオキシ
基を示し、R11及びR12のいずれか一方又はR13及びR
14のいずれか一方は水素原子を、他方はヒドロキシ基、
低級アルカノイルオキシ基又はヒドロキシ基が低級アル
カノイル基で保護されていてもよい単糖残基を示す(た
だし、当該他方のうちの一つはヒドロキシ基又は低級ア
ルカノイルオキシ基を示す)〕で表わされるグリコシ
ド。1. A compound represented by the general formula (A): [In the formula, R 1 represents a hydrogen atom, a monosaccharide residue, a disaccharide residue or a trisaccharide residue in which a lower alkyl group or a hydroxy group may be protected by a lower alkanoyl group, and R 2 represents a hydrogen atom, A methyl group or a hydroxymethyl group, R 3 and R 8 are a hydroxy group, —CH 2 OR 3 ′ or —COO.
R 8 '(where R 3' represents a hydrogen atom or a lower alkanoyl group, R 8 'represents a hydrogen atom or a lower alkyl group)
And one of R 4 and R 5 , one of R 6 and R 7 , or one of R 9 and R 10 is a hydrogen atom, and the other is a hydroxy group or a lower alkanoyloxy group, 11 or R 12 or R 13 and R
One of 14 is a hydrogen atom, the other is a hydroxy group,
A glycoside represented by a lower alkanoyloxy group or a monosaccharide residue in which a hydroxy group may be protected by a lower alkanoyl group (wherein one of the other is a hydroxy group or a lower alkanoyloxy group)] .
して含有する抗肝炎剤。2. An anti-hepatitis agent containing the glycoside according to claim 1 as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4228756A JPH0673084A (en) | 1992-08-27 | 1992-08-27 | Glycoside and antihepatitic agent comprising the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4228756A JPH0673084A (en) | 1992-08-27 | 1992-08-27 | Glycoside and antihepatitic agent comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0673084A true JPH0673084A (en) | 1994-03-15 |
Family
ID=16881339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4228756A Pending JPH0673084A (en) | 1992-08-27 | 1992-08-27 | Glycoside and antihepatitic agent comprising the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0673084A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999059578A1 (en) * | 1998-05-19 | 1999-11-25 | Research Development Foundation | Triterpene compositions and methods for use thereof |
JP2008545773A (en) * | 2005-06-06 | 2008-12-18 | ビーエーエスエフ ソシエタス・ヨーロピア | Process for removing salts from reaction mixtures containing alkoxycarbonylaminotriazines |
-
1992
- 1992-08-27 JP JP4228756A patent/JPH0673084A/en active Pending
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999059578A1 (en) * | 1998-05-19 | 1999-11-25 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US6444233B1 (en) | 1998-05-19 | 2002-09-03 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US6689398B2 (en) | 1998-05-19 | 2004-02-10 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US6746696B2 (en) | 1998-05-19 | 2004-06-08 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US6962720B2 (en) | 1998-05-19 | 2005-11-08 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US7105186B2 (en) | 1998-05-19 | 2006-09-12 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US7670632B2 (en) | 1998-05-19 | 2010-03-02 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US7985435B2 (en) | 1998-05-19 | 2011-07-26 | Research Development Foundation | Triterpene compositions and methods for use thereof |
US8324177B2 (en) | 1998-05-19 | 2012-12-04 | Research Development Foundation | Triterpene compositions and methods for use thereof |
JP2008545773A (en) * | 2005-06-06 | 2008-12-18 | ビーエーエスエフ ソシエタス・ヨーロピア | Process for removing salts from reaction mixtures containing alkoxycarbonylaminotriazines |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1240989A (en) | Homodisaccharide hypoglycemic agents | |
US5763413A (en) | Lewis-associated compound, process for producing the same, and anti-inflammatory | |
US20030153512A1 (en) | Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same | |
Holland et al. | Favored conformation of tri-O-acetyl-. beta.-D-xylopyranosyl chloride. An all-axial tetrasubstituted six-membered ring | |
Lichtenthaler et al. | 4, 6-di-O-benzoyl-3-O-benzyl-α-d-arabino-hexopyranos-2-ulosyl bromide: A conveniently accessible glycosyl donor for the expedient construction of diantennary β-d-mannosides branched at O-3 and O-6 | |
US4885280A (en) | Novel 14-amino steroids | |
Carpani et al. | Saponins from Albizzia anthelmintica | |
JPH0524920B2 (en) | ||
Reed III et al. | Synthesis of thiolactose (4-S-β-d-galactopyranosyl-4-thio-d-glucopyranose) | |
US4537882A (en) | 4-Demethoxy-3'-desamino-2'-halo-anthracycline and pharmaceutical composition containing same | |
Garegg et al. | Synthesis of di-and tri-saccharides corresponding to receptor structures recognised by pyelonephritogenic E. coli fimbriae (pili) | |
Szurmai et al. | Glycosylated trehalose. Synthesis of the oligosaccharides of the glycolipid-type antigens from Mycobacterium smegmatis | |
Batey et al. | The selective benzoylation of monosaccharides | |
US4888417A (en) | Therapeutic and prophylactic agents for peptic ulcer | |
CN102796159A (en) | Dammarane glucosides and preparation method and application thereof | |
CN101781352A (en) | 20-O-glycosyl and protopanoxadiol compound and preparation method thereof | |
Higuchi et al. | Biologically active glycosides from Asteroidea, XXXI. Glycosphingolipids from the starfish Asterias amurensis versicolor Sladen, 2. Structure and biological activity of ganglioside molecular species | |
JPH0673084A (en) | Glycoside and antihepatitic agent comprising the same | |
KR0153478B1 (en) | Esculetin derivatives and method for manufacture thereof, use thereof and pharmaceutical composition | |
GB2101588A (en) | N-Acetylneuraminic acid derivatives and process for the preparation thereof | |
US4447600A (en) | N-Acetylneuraminic acid derivatives and the preparation thereof | |
Du et al. | Hepatoprotective aliphatic glycosides from three Goodyera species | |
Glaudemans et al. | Synthesis of the Two 2-O-Nitro-3, 5-di-Op-nitrobenzoyl-D-arabinofuranosyl Chlorides, an Anomeric Pair of Crystalline Pentofuranosyl Halides Having a Nonparticipating Group at C-2 | |
Fujiwara et al. | Synthesis of 3, 6-di-O-methylglucosyl disaccharides with methyl 3-(p-hydroxyphenyl) propionate as a linker arm and their use in the serodiagnosis of leprosy | |
JPH1160592A (en) | Cholestanol compound and medicine containing the same |